Litigation Details for ALVOGEN, INC. v. BECERRA (D.D.C. 2021)

ALVOGEN, INC. v. BECERRA (D.D.C. 2021)

Docket		Date Filed	2021-03-11
Court	District Court, District of Columbia	Date Terminated	2021-05-19
Cause	05:702 Administrative Procedure Act	Assigned To	Amy Berman Jackson
Jury Demand	None	Referred To
Patents	6,159,498; 7,579,019; 8,147,866; 9,655,843; 9,901,539
Link to Docket	External link to docket

Details for ALVOGEN, INC. v. BECERRA (D.D.C. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-09	25	Memorandum in Support of Motion for a Preliminary Injunction and Summary Judgme	submissions (U.S. Patent Nos. 7,579,019 (“the ’019 patent”) and 8,147,866 (“the ’866 patent)). (AR at FDA-… ’866 patent and U.S. Patent Nos. 9,655,843 (“the ’843 patent”) and 9,901,539 (“the ’539 patent”), both… the ’843 and ’539 patents, respectively). As neither of these patents was a patent that qualified Teva… (I) that no patent information for the RLD has been filed with FDA; or, for each patent listed in the…seeking approval, (II) that the patent has expired; (III) that the patent will expire on a particular date	External link to document
2021-03-11	6	Memorandum in Support	the cusp of expiring16) were 16 U.S. Patent No. 6,159,498 was also listed in the Orange Book at the… ’866 patent and U.S. Patent Nos. 9,655,843 (“the ’843 patent”) and 9,901,539 (“the ’539 patent”), both…submissions (U.S. Patent Nos. 7,579,019 (“the ’019 patent”) and 8,147,866 (“the ’866 patent)). See FDA Paragraph…21 Page 28 of 42 the ’866 patent and the ’019 patent. The ’019 patent expired in January 2020, however… the ’843 and ’539 patents, respectively). As neither of these patents was a patent that qualified Teva	External link to document